Medical School of Nantong University, Nantong, China.
Department of Clinical Research Center, Nantong First People's Hospital, The Second Affiliated Hospital of Nantong University, Nantong, China.
Cancer Res Treat. 2020 Oct;52(4):1067-1083. doi: 10.4143/crt.2020.187. Epub 2020 May 8.
RIOK1 has been proved to play an important role in cancer cell proliferation and migration in various types of cancers-such as colorectal and gastric cancers. However, the expression of RIOK1 in breast cancer (BC) and the relationship between RIOK1 expression and the development of BC are not well characterized. In this study, we assessed the expression of RIOK1 in BC and evaluated the mechanisms underlying its biological function in this disease context.
We used immunohistochemistry, western blot and quantitative real-time polymerase chain reaction to evaluate the expression of RIOK1 in BC patients. Then, knockdown or overexpression of RIOK1 were used to evaluate the effect on BC cells in vitro and in vivo. Finally, we predicted miR-204-5p could be a potential regulator of RIOK1.
We found that the expression levels of RIOK1 were significantly higher in hormone receptor (HR)-negative BC patients and was associated with tumor grades (p=0.010) and p53 expression (p=0.008) and survival duration (p=0.011). Kaplan-Meier analysis suggested a tendency for the poor prognosis. In vitro, knockdown of RIOK1 could inhibit proliferation, invasion, and induced apoptosis in HR-negative BC cells and inhibited tumorigenesis in vivo, while overexpression of RIOK1 promoted HR-positive tumor progression. MiR-204-5p could regulate RIOK1 expression and be involved in BC progression.
These findings indicate that RIOK1 expression could be a biomarker of HR-negative BC, and it may serve as an effective prognostic indicator and promote BC progression.
RIOK1 已被证明在多种癌症（如结直肠癌和胃癌）的癌细胞增殖和迁移中发挥重要作用。然而，RIOK1 在乳腺癌（BC）中的表达及其与 BC 发展的关系尚未得到很好的描述。在本研究中，我们评估了 RIOK1 在 BC 中的表达，并评估了其在该疾病背景下的生物学功能的潜在机制。
我们使用免疫组织化学、Western blot 和定量实时聚合酶链反应来评估 BC 患者中 RIOK1 的表达。然后，使用 RIOK1 的敲低或过表达来评估其对体外和体内 BC 细胞的影响。最后，我们预测 miR-204-5p 可能是 RIOK1 的潜在调节因子。
我们发现，RIOK1 的表达水平在激素受体（HR）阴性 BC 患者中显著升高，与肿瘤分级（p=0.010）、p53 表达（p=0.008）和生存时间（p=0.011）相关。Kaplan-Meier 分析表明，预后不良的趋势。在体外，RIOK1 的敲低可以抑制 HR 阴性 BC 细胞的增殖、侵袭和诱导凋亡，并抑制体内肿瘤发生，而 RIOK1 的过表达则促进 HR 阳性肿瘤的进展。miR-204-5p 可以调节 RIOK1 的表达并参与 BC 的进展。
这些发现表明 RIOK1 的表达可能是 HR 阴性 BC 的一个生物标志物，它可能作为一个有效的预后指标，并促进 BC 的进展。
